2-甲氧基吡啶-3-硼酸频哪醇酯 | 532391-31-4

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-甲氧基吡啶-3-硼酸频哪醇酯
• 中文别名: 2-甲氧基-3-(4,4,5,5-四甲基-1,3,2-二杂氧戊硼烷-2-基)吡啶；2-甲氧基吡啶-3-硼酸频哪酯
• 英文名称: 2-methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
• CAS: 532391-31-4
• 化学式: C₁₂H₁₈BNO₃
• 分子量: 235.091
• InChiKey: JEJYNUCGRAHMDO-UHFFFAOYSA-N

物化性质

• 熔点：
  59-61°C
• 沸点：
  329.4±27.0 °C(Predicted)
• 密度：
  1.06±0.1 g/cm3(Predicted)
• 稳定性/保质期：
  按规定使用和贮存的情况下不会分解，避免接触氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  1.39
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  40.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2934999090
• 危险标志：
  GHS07
• 危险性描述：
  H319
• 危险性防范说明：
  P305 + P351 + P338

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
2-Methoxypyridine-3-boronic acid, pinacol ester
Product Name:
Synonyms: 2-Methoxy-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)pyridine

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
2-Methoxypyridine-3-boronic acid, pinacol ester
Ingredient name:
CAS number: 532391-31-4

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C12H18BNO3
Molecular weight: 235.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-甲氧基吡啶-3-硼酸频哪醇酯 在 双氧水 、 仲丁基锂 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 正己烷 、 环己烷 、 水 为溶剂， 反应 0.92h， 生成 (S)-1-(2-methoxypyridin-3-yl)-1-phenylethanol
  参考文献：
  名称：

  锂化-硼化方法不对称合成1-杂芳基-1-芳烷基叔醇和1-吡啶基-1-芳基乙烷

  摘要：

  高度对映体富集的α-杂环叔醇的合成是通过对构型稳定的锂化氨基甲酸酯和杂环频哪醇硼酸酯进行锂化-硼化，然后进行氧化来实现的。使用TBAF·3H 2 O或CsF对α-杂环叔硼酸酯进行原硼酸脱硼，可以得到较高对映体含量的高对映体富集的1-吡啶基-1-芳基乙烷。

  DOI：

  10.1021/ol400289v
• 作为产物：
  描述：

  3-溴-2-甲氧基吡啶 、 联硼酸频那醇酯 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium acetate 作用下， 以 甲苯 为溶剂， 生成 2-甲氧基吡啶-3-硼酸频哪醇酯
  参考文献：
  名称：

  AROMATIC HETEROCYCLIC COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF

  摘要：

  公开了一种芳香杂环化合物，其中间体，其制备方法，以及药物组合物及其用途。本发明的芳香杂环化合物是一种新的ALK5抑制剂，用于治疗和/或预防各种ALK5介导的疾病。

  公开号：

  US20210032241A1

文献信息

• 溴二氟甲硫氧基类化合物、中间体，及其制备 方法和应用
  申请人：中国科学院上海有机化学研究所

  公开号：CN107011219B

  公开（公告）日：2018-11-27

  本发明公开了一种溴二氟甲硫氧基类化合物、中间体，及其制备方法及其应用。本发明提供了一种化合物I，其中，R1、R2和R3各自独立地为H、C1～C10的烷基、C6～C10的芳基，且R1、R2和R3中至少两个不同时为H；或所述的R1、R2和R3中任意两个连接，形成C3～C6的环烷烃；或所述的R1、R2和R3中任意两个连接，形成C3～C6的环烷烃，并与苯环形成并环。本发明提供了一种所述的化合物I的制备方法，其包括如下步骤：在有机溶剂中，将化合物II、Cl2和化合物III进行反应，得到所述的化合物I即可。使用本发明的溴二氟甲硫氧基类化合物I，能实现芳烃或杂芳烃化合物上直接引入溴二氟甲硫基。
• Synthesis and Reactivity of α‐Cumyl Bromodifluoromethanesulfenate: Application to the Radiosynthesis of [ ¹⁸ F]ArylSCF ₃
  作者：Jiang Wu、Qunchao Zhao、Thomas C. Wilson、Stefan Verhoog、Long Lu、Véronique Gouverneur、Qilong Shen

  DOI：10.1002/anie.201813708

  日期：2019.2.18

  A highly reactive electrophilic bromodifluoromethylthiolating reagent, α-cumyl bromodifluoro-methanesulfenate 1, was prepared to allow for direct bromodifluoromethylthiolation of aryl boron reagents. This coupling reaction takes place under copper catalysis, and affords a large range of bromodifluoromethylthiolated arenes. These compounds are amenable to various transformations including halogen exchange

  制备了高反应性的亲电溴二氟甲基硫醇化试剂，α-枯基溴二氟甲基甲磺酸盐1，以允许芳基硼试剂的直接溴二氟甲基硫醇化。该偶联反应在铜催化下发生，并提供了大范围的溴二氟甲基硫醇化的芳烃。这些化合物可进行各种转化，包括与[18 F] KF / K222进行卤素交换，该过程可从相应的芳基硼酸频哪醇酯分两步获得[18 F]芳基SCF3。
• [EN] INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION<br/>[FR] INHIBITEURS D'HISTONE DÉSACÉTYLASE UTILES POUR LE TRAITEMENT OU LA PRÉVENTION D'UNE INFECTION PAR LE VIH
  申请人：MERCK SHARP & DOHME

  公开号：WO2020028150A1

  公开（公告）日：2020-02-06

  The present invention relates to Compounds of Formula (I): Formula (I) and pharmaceutically acceptable salts or prodrug thereof, wherein R1, R2, R3, Ra, Rb, A and B are as defined herein. The present invention also relates to compositions comprising at least one compound of Formula (I), and methods of using the compounds of Formula (I) for treating or preventing HIV infection in a subject.

  本发明涉及公式（I）的化合物：公式（I）及其药学上可接受的盐或前药，其中R1、R2、R3、Ra、Rb、A和B如本文所定义。本发明还涉及包含至少一种公式（I）化合物的组合物，以及使用公式（I）化合物治疗或预防受试者的HIV感染的方法。
• AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS
  申请人：Allen Jennifer R.

  公开号：US20100160280A1

  公开（公告）日：2010-06-24

  Pyridine and pyrimidine compounds: or a pharmaceutically acceptable salt thereof, wherein m, n, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , and Y are as defined in the specification; or a pharmaceutically acceptable salt thereof, wherein ring A, m, n, y, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , X 1 , X 2 , and ring A are as defined in the specification; and or a pharmaceutically acceptable salt thereof, wherein m, n, y, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 9 , X 1 , X 2 , and ring A are as defined in the specification; compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

  吡啶和嘧啶化合物： 或者是根据说明书中定义的药用可接受盐，其中m、n、R1、R2、R3、R4、R5、R6、R7、X1、X2、X3、X4、X5、X6、X7、X8和Y都有所定义； 或者是根据说明书中定义的药用可接受盐，其中环A、m、n、y、R2、R3、R4、R5、R6、R7、R8、R9、X1、X2和环A都有所定义； 或者是根据说明书中定义的药用可接受盐，其中m、n、y、R2、R3、R4、R5、R6、R7、R9、X1、X2和环A都有所定义；含有它们的组合物以及制备这类化合物的方法。还提供了通过抑制PDE10治疗可治疗的疾病或病症的方法，例如肥胖、非胰岛素依赖型糖尿病、精神分裂症、双相情感障碍、强迫症等。
• PYRROLOPYRIMIDINES AS CFTR POTENTIATORS
  申请人：CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC.

  公开号：US20180141954A1

  公开（公告）日：2018-05-24

  The present invention relates to compounds of Formula I, wherein R 1a , R 1b , R 2 , R 3 , R 4 , W, Y, and Z are as described herein, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compound, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sjögren's Syndrome, and other CFTR associated disorders.

  本发明涉及式I的化合物，其中R1a、R1b、R2、R3、R4、W、Y和Z如本文所述，并且其药学上可接受的盐。这些化合物是囊性纤维化跨膜传导调节器（CFTR）的增效剂。本发明还揭示了包括该化合物的药物组合物，可选地与额外治疗剂结合，并通过给予这些化合物来增强哺乳动物（包括人类）CFTR的方法。这些化合物可用于治疗囊性纤维化（CF）、哮喘、支气管扩张、慢性阻塞性肺病（COPD）、便秘、糖尿病、干眼症、胰腺炎、鼻窦炎、Sjögren综合征和其他与CFTR相关的疾病。